US Healthcare Bill's Failure Could Have Unpleasant Ripple Effects For Pharma
Executive Summary
Having sat on the sidelines during the unsuccessful effort to repeal and replace Obamacare, the pharma industry may find the rest of its legislative agenda, from taxes to even user fee reauthorization, could become more difficult.
You may also be interested in...
PhRMA And Trump: 'Go Boldly,' Or Tread Carefully?
Brand name industry’s image campaign promises to 'Go Boldly' – but there has been nothing bold about its public response to the Trump Administration’s efforts to repeal the Affordable Care Act, the President’s strong words on drug pricing, or even proposed cuts to NIH funding and FDA. Treading carefully makes a lot of sense – but is there a line that PhRMA won’t let the Administration cross?
User Fee Bill Could Become Ensnared In US Abortion Politics
Amendment defunding Planned Parenthood is one ACA repeal refugee that could hitch a ride with user fee bill, which would be 'problematic,' to say the least, for Democrats.
US FDA Faces Hiring Slowdown, Funding Cuts In Trump's FY 17 Plan
Suggested cuts to appropriations bill funding government for remainder of fiscal year 2017 also includes 'administrative savings.'